First Meeting of the Oligonucleotide Therapeutics Society
Thursday, September 15, 2005 - Sunday, September 18, 2005
With the completion of the human genome project, and the sequencing of various model organisms, oligonucleotide-based gene-silencing techniques are emerging as important tools for functional genomics research. Additionally, nucleic acid–based therapeutics are currently being developed as treatments for a variety of diseases. The appeal of these technologies is their ability to target specific genes, in particular those involved in the pathophysiology and etiology of various diseases. This meeting will integrate basic science, drug discovery, and preclinical and clinical research so that those working in academic and industry settings can develop a mutual understanding of the various technologies offered and their applications in both scientific research and as therapeutic agents.
The Oligonucleotide Therapeutics Society
The Oligonucleotide Therapeutics Society is an open, nonprofit forum whose mission is to foster academic and industry-based research and development of oligonucleotide therapeutics (RNAi, CpG, antisense, and others). For information, contact the Oligonucleotide Therapeutics Society: University Hospital Zurich, Department of Oncology, Haldeliweg 4, CH-8044 Zurich, Switzerland.
- Fritz Eckstein (Max-Planck Institute for Experimental Medicine)
- Alan M. Gewirtz (University of Pennsylvania School of Medicine)
- Gunther Hartmann (Ludwig-Maximilians-University of Munich)
- Ryszard Kole (University of North Carolina, Chapel Hill)
- Art Krieg (Coley Pharmaceutical Group, Inc.)
- Bernard LeBleu (University of Montpellier)
- Brett Monia (ISIS Pharmaceuticals)
- John Rossi (Beckman Research Institute of the City of Hope)
- Georg Sczakiel (University of Lubeck)
- Cy Stein (Albert Einstein College of Medicine)
- Thomas Tuschl (The Rockefeller University)